Free express shipping over $999 · Verified pharmaceuticals · Discreet packaging worldwide
OnlineMeds onlinemeds.org
Account Cart
Skip to order
Prescription only medicine

Tucanat 150 mg Tablet

Tucatinib 150 mg · Generic equivalent of Tukysa

Tucanat 150 mg Tablet is a trusted medication containing Tucatinib, designed for personal use under the guidance of a healthcare professional. Available for prescription-based international supply with discreet worldwide delivery.

Active ingredient
Tucatinib
Strength
150 mg
Form
Tablet
Manufacturer
Natco Pharma Ltd.
Made in
India
Prescription
Required
Commonly used forBreast Cancer
$535.00 per pack of 60 tablets

Prescription required — upload it at checkout.

Generic equivalent of Tukysa — up to 80% less than the branded price

Verified pharmacy Genuine medication Tracked shipping Medically reviewed by Nicholas Brain
Licensed Pharmacy Trust & safety
Licensed Manufacturers Every medicine from a licensed manufacturer
Dedicated Oncology Team Doctor + pharmacist review every order before dispatch
Worldwide Delivery UK · US · AU · EU · NZ — tracked and insured
About this medicine

What is Tucanat 150 mg Tablet?

Tucatinib is a targeted tablet for cancers driven by the HER2 protein. It is used for HER2-positive breast cancer that has spread — including to the brain — after earlier HER2-targeted treatment, taken together with trastuzumab and capecitabine; and for HER2-positive bowel (colorectal) cancer that has spread and been treated with chemotherapy, taken with trastuzumab.

It blocks HER2 very selectively, sparing the related EGFR receptor, which is why it causes less rash and diarrhoea than older dual HER2/EGFR inhibitors. It also reaches the brain, which matters because HER2-positive breast cancer often spreads there.

Tucatinib is taken twice a day, with or without food, continuously. Liver tests are checked regularly. It is a prescription-only medicine; a valid prescription must be provided at checkout.

How it works

How does Tucatinib work?

HER2 is a receptor on the surface of some breast and bowel cancer cells; when there is far too much of it, it sends a constant 'grow' signal into the cell. Tucatinib enters the cell and blocks the part of HER2 that passes that signal on. It is highly selective for HER2 over EGFR, its close relative, so it disrupts fewer normal-tissue signals than earlier drugs in this class. Combined with trastuzumab — an antibody that attaches to the outside of HER2 — the receptor is blocked at two points, and tucatinib's ability to cross into the brain extends that effect to brain metastases.

Selective binding

Tucatinib inhibits the HER2 kinase domain with roughly 1,000-fold selectivity over EGFR, so EGFR-driven skin and gut side effects are reduced.

Signal cut off

Blocking HER2 kinase stops downstream PI3K/AKT and MAPK growth signalling in HER2-amplified tumour cells.

Two-point blockade

With trastuzumab bound outside and tucatinib inside, HER2 is shut down at both ends; tucatinib's brain penetration extends the effect to CNS metastases.

Uses

What is Tucatinib used for?

HER2-positive advanced or metastatic breast cancer, including brain metastases

With trastuzumab and capecitabine, after at least one (EMA: two) prior anti-HER2 regimens.

FDA EMA CDSCO
HER2-positive, RAS wild-type metastatic colorectal cancer

With trastuzumab, after fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy.

FDA

Only your oncologist can determine whether this medicine is right for your diagnosis. The above is for information only.

Dosage

How to take Tucanat 150 mg Tablet

Your oncologist will prescribe your exact dose. The right dose for you depends on your weight, kidney and liver function, and — for some medicines — your genetic test results.

Always take exactly as prescribed. Do not change your dose or stop taking this medicine without speaking to your doctor first, even if you feel well.

Missed a dose? Skip a missed dose and take the next one at the usual time. Do not take two doses together. If you vomit, do not replace the dose.

With food? Take with or without food. Swallow whole with water; do not crush or chew. Avoid grapefruit and grapefruit juice.

Important safety information

Safety & warnings

Please read this section before taking Tucanat 150 mg Tablet and discuss any concerns with your oncologist.

Common side effects

Side effects affect some people, not everyone. Most are manageable — let your treatment team know about anything that concerns you.

  • Diarrhoea
  • Hand-foot syndrome (mostly from capecitabine)
  • Nausea, vomiting, reduced appetite
  • Tiredness (fatigue)
  • Raised liver enzymes (ALT, AST) and bilirubin
  • Mouth soreness
  • Headache, nosebleeds, rash
  • Raised creatinine (a lab effect, not kidney damage)

Contact your doctor immediately if you notice:

  • Diarrhoea that is severe, lasts more than a day, or comes with fever or dehydration Contact your team the same day; start the anti-diarrhoeal you were given at the first loose stool.
  • Yellow skin or eyes, dark urine, pain under the right ribs Contact your oncologist immediately — possible liver injury; liver tests are checked every three weeks.
  • Fever with chills, or signs of infection Contact your team — infection risk mainly comes from the capecitabine partner.
  • Chest pain, breathlessness, swollen ankles Seek urgent review — trastuzumab in the combination can affect the heart.
  • New headache, weakness, confusion or vision change Seek urgent assessment — these may relate to brain metastases and need imaging.

Important: tell your doctor about these medicines

Taking Tucatinib with certain other medicines can be dangerous. Always tell every doctor, dentist, and pharmacist about all medicines you are taking.

  • Strong CYP2C8 inhibitors (gemfibrozil) Major

    Increase tucatinib levels markedly.

  • Strong CYP2C8 or CYP3A inducers (rifampicin, phenytoin, carbamazepine, St John's wort) Major

    Reduce tucatinib levels and may make it less effective.

  • CYP3A substrates with a narrow margin (midazolam, tacrolimus, some statins, certain anticoagulants) Major

    Tucatinib is a strong CYP3A inhibitor and raises their levels.

Pregnancy & breastfeeding

Tucatinib can harm an unborn baby. It should not be used in pregnancy, and women who could become pregnant should use effective contraception during treatment and for at least one week after the last dose — longer for the trastuzumab and capecitabine partners.

Do not breastfeed during treatment or for one week after the last dose.

Tucatinib may reduce fertility in women. Discuss fertility preservation before starting if relevant.

For full prescribing information see: FDA prescribing information: Tukysa (tucatinib) — DailyMed

Storage

How to store Tucanat 150 mg Tablet

Temperature

Store at 20–25°C (68–77°F).

Light & moisture

Keep in the original bottle with the desiccant; protect from moisture.

Keep away from children

Keep out of the sight and reach of children.

Safe handling

Anticancer medicine: swallow whole, do not crush; wash hands after handling. Return unused tablets to a pharmacy.

Travelling

Carry in the original bottle with your prescription and an oncologist's letter; you will also need your capecitabine and your infusion schedule.

Reviewed for accuracy

Medically reviewed content

Nicholas Brain

Nicholas Brain

B.Pharm, M.Pharm

Nicholas Brain is a licensed clinical pharmacist with 16 years of experience. He holds a B.Pharm and M.Pharm from Kannur University. At OnlineMeds, he reviews medicine and health content to help ensure it is accurate, evidence-based, and easy to understand.

Our commitment to you

How we support oncology patients

We understand that accessing the right cancer medicine can feel overwhelming. Here is what you can expect from us.

Personal oncology support

Every enquiry is reviewed by our oncology doctor and pharmacist team — not an automated system.

Genuine, verified medicine

Sourced exclusively from licensed pharmaceutical manufacturers. Every batch is traceable from origin to your door.

Prescription checked before dispatch

We verify every prescription with our internal medical team. No shortcuts, no exceptions.

Cold-chain logistics

Temperature-sensitive medicines shipped with appropriate packaging to maintain integrity.

Discreet, plain packaging

No pharmacy branding or product name on the outer packaging.

Up to 80% less than branded

Generic oncology medicines contain the same active ingredient as the originator brand — at a fraction of the cost.

FAQ

Frequently asked questions

Is Tucatinib the same as Tukysa?

Tucatinib is the active ingredient in Tukysa. A generic Tucatinib medicine contains the same active ingredient at the same strength and is taken the same way — the main difference is cost. Always use it as prescribed by a licensed medical professional.

How is Tucanat 150 mg Tablet different from lapatinib or neratinib?

All three are HER2 tyrosine kinase inhibitors taken by mouth. Tucatinib is far more selective for HER2 over EGFR, so it causes less rash and diarrhoea than lapatinib and neratinib, and it was studied specifically in people with brain metastases. Your oncologist chooses between them based on your history and what is available.

[2] NCI Drug Information: Tucatinib

Why is Tucanat 150 mg Tablet given with trastuzumab and capecitabine?

The three attack the tumour differently — trastuzumab blocks HER2 from outside the cell, tucatinib from inside, and capecitabine is chemotherapy. The combination was what the approval studies tested; tucatinib is not used on its own.

[1] FDA prescribing information: Tukysa (tucatinib) — DailyMed

Does Tucanat 150 mg Tablet work on brain metastases?

Tucatinib crosses into the brain and the combination was studied in people with brain metastases, including those still growing. It is one of the reasons it is chosen for HER2-positive breast cancer that has spread there. Your oncologist will monitor with scans.

[3] EMA: Tukysa — European public assessment report

What should I do about diarrhoea?

Diarrhoea is the most common side effect of the combination. Your oncologist will usually prescribe loperamide to keep at home, to start at the first loose stool. Drink plenty of fluids and contact your team if it is severe or lasts more than a day — a short pause or dose reduction usually settles it.

[4] Macmillan Cancer Support: Tucatinib (Tukysa)

Why has my creatinine gone up?

Tucatinib blocks the transport of creatinine into the urine, so the blood level rises without the kidneys being harmed. Your team knows this and will use other tests if kidney function needs checking.

[1] FDA prescribing information: Tukysa (tucatinib) — DailyMed

Is Tucanat 150 mg Tablet the same as Tukysa?

Tucanat 150 mg Tablet contains the same active ingredient, tucatinib, at the same 150 mg strength as the originator brand Tukysa. Generic medicines must meet the same regulatory standards for quality, safety and effectiveness. Used as prescribed by a licensed medical professional.

[3] EMA: Tukysa — European public assessment report

Can I take Tucanat 150 mg Tablet with food?

Yes, with or without food — food does not meaningfully change absorption. Avoid grapefruit, which affects how the drug is cleared.

[1] FDA prescribing information: Tukysa (tucatinib) — DailyMed

Do I need a prescription to order Tucanat 150 mg Tablet?

Yes. Tucatinib is prescription-only. Upload your oncologist's prescription at checkout; our pharmacist team reviews it before dispatch. Used as prescribed by a licensed medical professional.

Sources

References

  1. 1. FDA prescribing information: Tukysa (tucatinib) — DailyMed. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=tukysa U.S. National Library of Medicine. Accessed 13 Sep 2026.
  2. 2. NCI Drug Information: Tucatinib. https://www.cancer.gov/about-cancer/treatment/drugs/tucatinib National Cancer Institute. Accessed 13 Sep 2026.
  3. 3. EMA: Tukysa — European public assessment report. https://www.ema.europa.eu/en/medicines/human/EPAR/tukysa European Medicines Agency. Accessed 13 Sep 2026.
  4. 4. Macmillan Cancer Support: Tucatinib (Tukysa). https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/tucatinib Accessed 13 Sep 2026.
Medical disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional — specifically your oncologist — before starting, changing, or stopping any medication. Information is based on NDA #213411, NCI Drug Information, and NHS patient information.
Editorial policy Privacy policy Terms & conditions
Shopping cart
Close
Shop
0 items Cart
My account